IRA im­pact on bio­phar­ma: Lat­est dis­clo­sures range from un­known to neg­a­tive

Drug­mak­ers are at­tempt­ing to de­tail how they ex­pect Medicare’s drug price “ne­go­ti­a­tions” (a term now co-opt­ed by the bio­phar­ma in­dus­try as “price set­ting”) to im­pact their busi­ness­es as CMS be­gins to lay out pric­ing rules for a small sub­set of the high­est spend­ing sin­gle-source drugs and bi­o­log­ics re­im­bursed un­der Medicare Part B and Part D.

The ini­tial “sky is falling” at­ti­tude from the bio­phar­ma in­dus­try has been tem­pered with more un­der­stand­ing of what’s com­ing, and even No­var­tis CEO Vas Narasimhan point­ed to its breast can­cer drug Kisqali as a like­ly tar­get for CMS ne­go­ti­a­tions near the end of this decade.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN